Recent Articles from GlobeNewswire

LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Alexandria Real Estate Equities, Inc. (“Alexandria” or “the Company”) (NYSE: ARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE: CBT) today announced that it will release operating results for the first quarter of fiscal 2026 on Tuesday, February 3, 2026, after the market close. The Company will host a conference call and live webcast to review the first quarter results beginning at 8:00 am (ET) on Wednesday, February 4, 2026.

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA.“Year over year, Ocugen’s presence at the JPM Healthcare Conference has evolved and we are delighted to share the potential of our modifier gene therapy platform along with clinical development progress,” said Dr. Musunuri. “This premier conference is the optimal way to kick off Ocugen’s catalyst-rich 2026 and engage in critical conversations with potential strategic partners and the investment community.”In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will be on site in San Franciso all week to conduct one-on-one meetings highlighting the Company’s business strategy on the path toward filing three BLAs in the next two years including the rolling BLA of OCU400 for retinitis pigmentosa this year.Details regarding the presentation are as follows:Date: Thursday, January 15, 2026Time: 9:45 - 10:25 a.m. PST Location: Colonial Room, MezzanineA live video webcast of the presentation will be available on the events page of the Ocugen investor site. The webcast replay will be available for a limited time following the event.About Ocugen, Inc.Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.Contact:Tiffany HamiltonAVP, Head of CommunicationsTiffany.Hamilton@ocugen.com

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”).

CHAPEL HILL, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IPACE-HIV study (Improving Physical Ability and Cellular Senescence Elimination in HIV), also known as A5426. IPACE-HIV is a phase 2, double-blind, randomized study evaluating the safety, tolerability, and efficacy of dasatinib and quercetin in improving physical function outcomes in people living with HIV who are frail or exhibit symptoms that they may become frail.

Proposed Transaction Expected to Expand Ready-to-Drink Product Portfolio, Enhance White Tea Value Chain, and Broaden Health-Oriented Consumption Scenarios

What To Know: 

Appointments strengthen newcleo's executive team as company advances its nuclear energy and fuel recycling business and prepares for next phase of growth

First Commercial Multi-Site Deployment With a National Construction Leader; Expands a Long-Standing Customer Relationship Across Multiple U.S. States

WASHINGTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical cognitive conditions — along with MRI and PET images in Bio-Hermes-002 —as well as numerous races and ethnicities to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias.

MIAMI, FL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- RenX Enterprises Corp. (NASDAQ: RENX) (the “Company”) today provided an update on a year that management views as transformational, reflecting a fundamental evolution of the Company’s operating profile, financial performance, and strategic direction.

MONTREAL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cerro de Pasco Resources Inc. (TSXV CDPR) (OTCQB GPPRF) (FRA N8HP) (the Company or CDPR) is pleased to provide an operational review and corporate update highlighting key workstreams completed and consolidated at the Quiulacocha Tailings Project, as the Company transitions toward the next stage of project execution.

-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies-

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company’s quarterly dividend over the previous quarter’s dividend.

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule

SAN JOSE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced that its management will present at the following upcoming financial community event:

2025 Closes with Accelerating Inflation and Seven Consecutive Month-over-Month Price Increases on Everyday Consumer Goods

Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026

EL MONTE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that Larry Wu, its Founder and Chief Executive Officer, will present at the 28th Annual Needham Growth Conference on Friday, January 16, 2026, at 2:15 p.m. ET/11:15 a.m. PT.

BEIJING, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Global Mofy AI Limited (the “Company” or “Global Mofy”) (Nasdaq: GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced its financial results for the fiscal year ended September 30, 2025.

-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 --

CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced the appointment of Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer. Dr. Eck brings more than three decades of oncology drug discovery and development leadership across academia, biotechnology and large pharmaceutical companies.

Licensing of scientific discoveries from University of Cambridge and University of Edinburgh is aimed to speed translation and access to life-saving diagnostics for women worldwide.

-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 --

Acquisition Strengthens Data Connectivity Across the Wealth and Private Markets Ecosystem

Members gain access to savings on AMI brands Gentek® Building Products and ASCEND® Composite Cladding

ATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Crayhill Capital Management (“Crayhill”) and Monarch Private Capital (“Monarch”) are pleased to announce a strategic joint venture to facilitate hybrid preferred tax equity investments for renewable energy projects, including utility-scale solar, battery storage, and distributed generation projects. Crayhill has committed $300 million of capital into the joint venture, Monarch JVT Funding. Through Monarch’s best-in-class platform, the JV will invest in tax partnerships that will facilitate fair market value tax basis for renewable energy developers.

BERKELEY, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced that it is revising its roadmap and adjusting the date for general availability of its 108-qubit quantum computing system, Cepheus™-1-108Q. Cepheus-1-108Q is now expected to reach general availability around the end of the first quarter of 2026.

RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Attindas Hygiene Partners’ growth strategy realized an important step forward today with its acquisition of Societá Italiana Lavorazione Cellulosa (SILC S.p.A.). Attindas executed a share purchase agreement with SILC, acquiring all shares of the 53-year-old, family-owned company.

LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- NordPass, a leading password manager, simplifies secure logins by including Authenticator on multiple devices in the application for personal use. The time-based one-time password (TOTP) support enables users to add an extra layer of security to their accounts with two-factor authentication, without the need to download or install additional applications. Authentication codes are synchronized within the account, letting users access them on both the mobile app or browser extension.

TORONTO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, today announced the preliminary results of its substantial issuer bid (the “SIB”), pursuant to which Altus Group offered to purchase for cancellation a number of its common shares (“Shares”) for an aggregate purchase price not to exceed C$350 million at a purchase price of not less than C$50.00 and not more than C$57.00 per Share. The SIB expired at 5:00 p.m. (Toronto time) on Thursday, January 8, 2026 (the “Expiration Time”).

Rakesh Panda appointed Chief Information Officer

$3.1 Billion Unsecured Funding Offering Strengthens Capital Structure and Marks Transformational Credit Profile Enhancement

Palmetto Publishing Announces the Release of KNIGHTSTORM

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending positive results, an NDA submission is planned for the second half of 2026

LAS VEGAS, Jan. 09, 2026 (GLOBE NEWSWIRE) -- AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), a leading AI-driven robotics solutions company, today announced its participation at CES® 2026. The Company demonstrated its latest artificial intelligence–powered technologies, headlined by Kyro™, its proprietary quadruped robotic platform.

Seasoned Capital Markets and Financial Executive to Drive Strategic Growth and Market Expansion

APOPKA, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) -- O2B Early Education, a trusted leader in early childhood education, is proud to announce the opening of its 83rd location, O2B Kids Apopka, continuing its mission to inspire young learners and support families through high-quality, engaging early education.

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors.

Celebration, FL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech enterprise, today announced an initial closing of an $11,000,000 note under its previously announced $250 million private placement convertible note facility (the “Note Facility”). The Company’s total available financing capacity, including the initial closing, is $1.25 billion when combined with its existing $1 billion equity purchase facility. La Rosa will deploy this capital to establish a strategic reserve, providing the liquidity and financial agility to scale its AI infrastructure strategy and develop a premium real estate portfolio of advanced data center facilities optimized for AI workloads. 

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease.

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference

New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation

SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) are being presented as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO-GI), taking place January 8-10 in San Francisco, CA.

DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in therapies for patients with elevated triglycerides (TG) and shared its perspective on how these developments stand to shape patient access and treatment strategies. Specifically, new therapies for these patients are likely to expand the use of existing, proven options over time, including Amarin’s VASCEPA®/VAZKEPA® (icosapent ethyl), an effective, safe, oral therapy that has been prescribed more than 25 million times to patients globally. In addition, through its approved indication for severe hypertriglyceridemia (sHTG), which is defined as TG ≥500 mg/dL, as well as strong clinical evidence, affordability, and broad reimbursement, VASCEPA/VAZKEPA aligns with current payor-driven step therapy programs, which require patients to try existing safe and efficacious treatment options before newer, more expensive sHTG alternatives.

Strategic Transaction Accelerates iHerb’s U.S. Business and Solidifies Commitment to the Vitamins, Minerals and Supplements Category

WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today provided an update on the regulatory approval of Anaphylm™ and its business.

SHENZHEN, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services in China, today announced that it has entered into a strategic partnership with Xiaoe Inc. (“Xiaoe”) to integrate its intelligent push notification solution, JPush, into Xiaoe’s flagship private domain SaaS platform.

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule.

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines' Memorial Club in San Francisco, California, during J.P. Morgan Healthcare Conference Week.

ADELAIDE, Australia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced today that its executive team will attend Biotech Showcase 2026 in San Francisco, January 12-14, to meet with innovative biotech sponsors and highlight the company’s newly launched Early Phase Center of Excellence for Biotechs.

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) (“Brookfield Asset Management”) today announced it has received the requisite approval for the renewal of its normal course issuer bid providing the option to purchase up to 36,946,177 Class A Limited Voting Shares (“Class A Shares”), representing approximately 10% of the public float of Brookfield Asset Management’s outstanding Class A Shares. Purchases under the bid will be made on the open market through the facilities of the New York Stock Exchange (“NYSE”), Toronto Stock Exchange (“TSX”), and/or alternative trading systems. The period of the normal course issuer bid will extend from January 13, 2026 to January 12, 2027, or an earlier date should Brookfield Asset Management complete its purchases. Brookfield Asset Management will pay the market price at the time of acquisition for any Class A Shares purchased or such other price as may be permitted.

MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, as well as updates on the commercial launch and the clinical pipeline. These updates will be discussed during Liquidia’s participation in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–14, 2026, in San Francisco. The Company plans to report fully audited financial results for the year ended December 31, 2025, in February 2026.

Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history.

FINRA Daily List Confirms “ Dividend Payable in Another Security” for DOGP

MONACO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Knowledge-sharing, innovation and collective commitment. The Yacht Club de Monaco kicks off a new season following its ‘Monaco, Capital of Advanced Yachting’ approach. In 2026, as part of its public service remit to enhance the Principality’s appeal, the Club confirms its role as a focal point of activity in Port Hercule and an international platform, while reinforcing its environmental and societal responsibility commitments. Top-level sport, youth training, the sustainable transition and maritime heritage define a year of events providing an arena for exchanges to build the future of yachting.

Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presented

Liege, Belgium – 9 January 2026 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology treatments for degenerative joint disease, will officially launch production of its first microparticle hydrogel after a ceremonial opening of its cleanroom manufacturing facility on 9 January 2026. After an investment worth multiple millions of euros, the state-of-the art facility enables annual production of a million prefilled syringes per year. The production will amongst others supply partner American Regent with Synoglide™, a novel treatment for osteoarthritis in the equine market, which has been launched recently in the US, for commercialization in veterinary markets worldwide.

Press release – No. 2 / 2026

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NOVAGOLD RESOURCES INC. (“NOVAGOLD” or the “Company”) (NYSE American, TSX: NG) announces that Donlin Gold LLC (“Donlin Gold”), which is owned 60% by NOVAGOLD and 40% by Paulson Advisers LLC (“Paulson”), and Glenfarne Alaska LNG, LLC (“Glenfarne”), majority owner and developer of the Alaska LNG Project (“Alaska LNG”), signed a non-binding Letter of Intent (LOI) for natural gas supply from the Alaska LNG Pipeline and the development of the infrastructure needed to deliver the gas and power the proposed mine.

A 2026 industry report examining THCA flower sales activity, strain demand, and self-reported buyer usage trends based on internal data from Exhale Wellness.

 Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, January 12-14, 2026, in San Francisco.

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of $23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Monte Rosa from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares and pre-funded warrants in the offering are to be sold by Monte Rosa. The offering is expected to close on or about January 12, 2026, subject to satisfaction of customary closing conditions.

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the pricing of its upsized initial public offering of 17,650,000 shares of its common stock at a price to the public of $18.00 per share. In addition, Aktis has granted the underwriters a 30-day option to purchase up to an additional 2,647,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Aktis, are expected to be approximately $318.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares of common stock are being offered by Aktis. Aktis’ common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “AKTS” on January 9, 2026. The offering is expected to close on January 12, 2026, subject to satisfaction of customary closing conditions.

LOS ANGELES, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alchera X (AX), a global leader in AI-powered facial recognition and computer vision solutions, is beginning 2026 on a strong trajectory, marked by high-profile national media coverage, executive leadership recognition from the Los Angeles Times, and strategic global engagement across the artificial intelligence ecosystem.

Miami, FL, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Soren Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $253,000,000.